AuthorsStewart, Alan L
AffiliationDepartment of Clinical Oncology, Christie Hospital, Manchester, UK.
MetadataShow full item record
AbstractCyclophosphamide induces moderate to severe emesis. The severity of emesis is dependent on the dose of cyclophosphamide and on the addition of other cytotoxic drugs. A review of the literature dividing studies according to the dose of cyclophosphamide and the specific cytotoxic combination shows that ondansetron plus dexamethasone provides optimal antiemetic therapy in patients receiving standard or high-dose cyclophosphamide (> or = 450 mg/m2). These studies also show that it is important to give antiemetic therapy to cover the prolonged duration emesis and nausea induced by these regimens, e.g. intravenous CMF/(F)AC/(F)EC. For continuous 'oral' (low-dose) CMF chemotherapy, oral ondansetron or oral metoclopramide plus intravenous (or possibly oral) dexamethasone are effective antiemetic therapies.
CitationOptimal control of cyclophosphamide-induced emesis. 1996, 53 Suppl 1:32-8 Oncology
- A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
- Authors: Bonneterre J, Chevallier B, Metz R, Fargeot P, Pujade-Lauraine E, Spielmann M, Tubiana-Hulin M, Paes D, Bons J
- Issue date: 1990 Jun
- Chemotherapy-induced emesis: management of early and delayed emesis in milder emetogenic regimens.
- Authors: Barrenetxea G, Schneider J, Centeno MM, Romero H, de la Rica M, Rodríguez-Escudero FJ
- Issue date: 1996
- Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil.
- Authors: Levitt M, Warr D, Yelle L, Rayner HL, Lofters WS, Perrault DJ, Wilson KS, Latreille J, Potvin M, Warner E
- Issue date: 1993 Apr 15
- High efficacy of a single oral dose of ondansetron 8 mg versus a metoclopramide regimen in the prevention of acute emesis induced by fluorouracil, doxorubicin and cyclophosphamide (FAC) chemotherapy for breast cancer.
- Authors: Bosnjak SM, Nesković-Konstantinović ZB, Radulović SS, Susnjar S, Mitrovi LB
- Issue date: 2000 Oct
- Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study.
- Authors: Buser KS, Joss RA, Piquet D, Aapro MS, Cavalli F, Haefliger JM, Jungi WF, Bauer J, Obrist R, Brunner KW
- Issue date: 1993 Jun